Kim et al., 2016 - Google Patents
A novel therapeutic approach using mesenchymal stem cells to protect against Mycobacterium abscessusKim et al., 2016
View PDF- Document ID
- 4148753499107585849
- Author
- Kim J
- Cha S
- Kim W
- Han S
- Cha S
- Kim H
- Kwon K
- Kim S
- Choi H
- Lee J
- Cho S
- Koh W
- Park Y
- Shin S
- Publication year
- Publication venue
- Stem Cells
External Links
Snippet
Recent studies have demonstrated the therapeutic potential of mesenchymal stem cells (MSCs) for the treatment of acute inflammatory injury and bacterial pneumonia, but their therapeutic applications in mycobacterial infections have not been investigated. In this study …
- 210000002901 Mesenchymal Stem Cells 0 title abstract description 237
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | A novel therapeutic approach using mesenchymal stem cells to protect against Mycobacterium abscessus | |
| Rajaram et al. | Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses | |
| Brooks et al. | NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages | |
| Gad et al. | Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria | |
| Le Bourhis et al. | MAIT cells detect and efficiently lyse bacterially-infected epithelial cells | |
| Bobosha et al. | T-cell regulation in lepromatous leprosy | |
| Wang et al. | Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression | |
| Bruns et al. | Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages | |
| Mendoza-Coronel et al. | Comparative evaluation of in vitro human macrophage models for mycobacterial infection study | |
| Salerno-Goncalves et al. | B cells modulate mucosal associated invariant T cell immune responses | |
| Bist et al. | The Nod1, Nod2, and Rip2 axis contributes to host immune defense against intracellular Acinetobacter baumannii infection | |
| Al‐Hassi et al. | Altered human gut dendritic cell properties in ulcerative colitis are reversed by Lactobacillus plantarum extracellular encrypted peptide STp | |
| Zhang et al. | Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell | |
| Shen et al. | Toll-like receptor 2-and MyD88-dependent phosphatidylinositol 3-kinase and Rac1 activation facilitates the phagocytosis of Listeria monocytogenes by murine macrophages | |
| Petruccioli et al. | Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages | |
| Khan et al. | Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis | |
| CA2968325A1 (en) | Intestinal microbiota and gvhd | |
| Arcos et al. | Lung mucosa lining fluid modification of Mycobacterium tuberculosis to reprogram human neutrophil killing mechanisms | |
| Kim et al. | A bacterial RTX toxin causes programmed necrotic cell death through calcium-mediated mitochondrial dysfunction | |
| Agrawal et al. | Human monocytic suppressive cells promote replication of Mycobacterium tuberculosis and alter stability of in vitro generated granulomas | |
| Jones et al. | CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling | |
| Frasca et al. | Hyper‐metabolic B cells in the spleens of old mice make antibodies with autoimmune specificities | |
| Naik et al. | Mouse bone marrow sca-1+ CD44+ mesenchymal stem cells kill avirulent mycobacteria but not mycobacterium tuberculosis through modulation of cathelicidin expression via the p38 mitogen-activated protein kinase-dependent pathway | |
| Lindgren et al. | Impaired IFN-γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients | |
| Board-Davies et al. | Oral mucosal lamina propria-progenitor cells exert antibacterial properties via the secretion of osteoprotegerin and haptoglobin |